for some people, many hae episodes happen without identifiable triggers, and response to the same trigger can vary significantly between individuals. for example, a specific trigger may cause a severe response in one patient but a mild or negligible response in another.
diagnosis and treatment of hereditary angioedema
diagnosis can be complex, involving assessing c1-inhibitor antigenic and functional levels, c4 complement levels, and potential genetic testing. without proper treatment, hae is highly disabling.
with limited data available on the clinical profile and disease burden of hae in canadians, researchers from the centre hospitalier universitaire de québec looked at the results from a patient survey conducted by the hae patient organization angio-oédeme héréditaire du québec from may 2019 to february 2020. they noted in the
journal of immunology research that prior to diagnosis, 69 per cent of participants underwent unnecessary treatments and procedures, with a 10-year delay between first symptoms and diagnosis. before starting their current treatment, 42 per cent experienced weekly hae attacks—most in the abdomen (89 per cent), followed by the larynx and feet (both 66 per cent), hands and face (both 63 per cent).
while most attacks were severe or moderate, almost half of participants waited more than an hour before getting medical attention at their last emergency department visit.
as well, hae was associated with decreased quality of life, impacting personal and professional life. patients with type iii were treated more often with tranexamic acid for long-term prophylaxis, and their condition was less controlled, resulting in more attacks and er visits.
as the authors wrote: “individuals face barriers at each step, from diagnosis to treatment and disease management. this indicates an urgent need for increased awareness and education on hae among canadian physicians, as well as continued advancements in treatment.”